DOCSLIB.ORG

Single Dose of Diclofenac Or Meloxicam for Control of Pain, Facial Swelling, and Trismus in Oral Surgery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Single Dose of Diclofenac Or Meloxicam for Control of Pain, Facial Swelling, and Trismus in Oral Surgery Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 (1):e127-34. Diclofenac versus meloxicam in oral surgery Journal section: Oral Surgery doi:10.4317/medoral.20925 Publication Types: Research http://dx.doi.org/doi:10.4317/medoral.20925 Single dose of diclofenac or meloxicam for control of pain, facial swelling, and trismus in oral surgery Mariana Orozco-Solís 1, Yazmín García-Ávalos 2, Celeste Pichardo-Ramírez 2, Francisco Tobías-Azúa 2, Juan-Ramón Zapata-Morales 3, Othoniel-Hugo Aragon-Martínez 4, Mario-Alberto Isiordia-Espinoza 5 1 DDS, Departamento de Estomatología, Unidad Médica Familiar No. 02, Instituto Mexicano del Seguro Social, Delegación San Luis Potosí, S.L.P., México 2 DDS, Departamento de Investigación y Postgrado, Escuela de Odontología, Universidad Cuauhtémoc, plantel San Luis Poto- sí, S.L.P., México 3 MSc, PhD, Departamento de Farmacia, División de Ciencias Naturales y Exactas, Universidad de Guanajuato, Guanajuato, México 4 MSc, PhD, Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, S.L.P., México 5 DDS, MSc, PhD, Departamento de Farmacología, Facultad de Odontología, Universidad Autónoma de Baja California, Mexi- cali, México Orozco-Solís M, García-Ávalos Y, Pichardo-Ramírez C, Tobías-Azúa F, Zapata-Morales JR, Aragon-Martínez OH, Isiordia-Espinoza MA. Single Correspondence: dose of diclofenac or meloxicam for control of pain, facial swelling, and Facultad de Odontología trismus in oral surgery. Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 Universidad Autónoma de Baja California (1):e127-34. Calle Zotoluca y Chinampas s/n http://www.medicinaoral.com/medoralfree01/v21i1/medoralv21i1p127.pdf Fraccionamiento Calafia C.P. 21040; Mexicali, México Article Number: 20925 http://www.medicinaoral.com/ [email protected] © Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946 eMail: [email protected] Indexed in: Science Citation Index Expanded Journal Citation Reports Received: 04/07/2015 Index Medicus, MEDLINE, PubMed Accepted: 19/08/2015 Scopus, Embase and Emcare Indice Médico Español Abstract Background: Postoperative pain associated with removal of mandibular third molars has been documented from moderate to severe during the first 24 hours after surgery, with pain peaking between 6 and 8 hours when a con- ventional local anesthetic is used. Dental pain is largely inflammatory, and evidence-based medicine has shown that nonsteroidal anti-inflammatory drugs are the best analgesics for dental pain. The aim of this study was to compare the analgesic, anti-inflammatory and anti-trismus effect of a single dose of diclofenac and meloxicam after mandibular third molar extraction. Material and Methods: A total of 36 patients were randomized into two treatment groups, each with 18 patients, using a series of random numbers: Group A, was administered 100 mg of diclofenac; and Group B, 15 mg of mel- oxicam. Drugs were administered orally 1 hour prior to surgery. We evaluated pain intensity, analgesic consump- tion, swelling, as well as trismus. Results: The results of this study showed that patients receiving 15 mg of meloxicam had less postoperative pain (P=0.04) and better aperture than those receiving 100 mg of diclofenac (P=0.03). The meloxicam group presented less swelling than diclofenac group; however, significant statistical differences were not observed. Conclusions: Data of this double-blind, randomized, parallel-group clinical trial demonstrated that patients re- ceiving 15 mg of preoperative meloxicam had a better postoperative analgesia and anti-trismus effect compared with who were given 100 mg of diclofenac after third molar extractions. Key words: Diclofenac, meloxicam, dental pain, trismus, third molar surgery. e127 Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 (1):e127-34. Diclofenac versus meloxicam in oral surgery Introduction ciated up to the day of the surgery, and difficulty of ex- In the majority of cases, removal of third molars will traction (grade II, III, or IV). Exclusion criteria included lead to a significant degree of tissue trauma, causing an use of analgesics 1 week before the procedure, gastritis, inflammatory reaction. The patient develops the com- peptic ulcer, pregnancy or lactation, and known hyper- mon postoperative symptoms and signs of pain, facial sensitivity to the medications used. swelling, dysfunction, and limited mouth opening (tris- - Randomization and blinding mus). The pain is typically brief and will peak in inten- A total of 36 patients from the Department of Maxil- sity in the early postoperative period. Facial swelling lofacial Surgery of the School of Dentistry at Cuauhté- and trismus will reach their characteristic maximum 48 moc University, San Luis Potosí, México, were recruit- to 72 h after surgery (1). ed. The patients were randomized into two treatment Evidence-based medicine has shown that Non-steroidal groups, each with 18 patients, using a series of ran- anti-inflammatory drugs (NSAID) comprise the best dom numbers: Group A, was administered 100 mg of analgesic for dental pain (2). The effects of NSAID are diclofenac; and Group B, 15 mg of meloxicam. Drugs the result of inhibiting Cyclo-oxygenase (COX) en- were administered orally 1 hour prior to surgery. The zymes, which catalyze the conversion of arachidonic algorithm is shown in (Fig. 1). Moreover, both patients acid into prostaglandins, which are fatty acids involved and an independent evaluator were blinded regarding in the generation of pain, inflammation, and fever (3). the treatment administered. Diclofenac is a commonly prescribed NSAID with an- - Interventions algesic, anti-inflammatory, and anti-pyretic properties After the administration of the assigned treatment, the that has been widely used in pain control with good tooth was removed. All of the surgical procedures were effectiveness after third molar surgery (4,5). However, carried out at the Department of Oral and Maxillofacial traditional NSAID such as diclofenac - have been wide- Surgery by the same surgeon. Anesthesia was through ly used to treat pain, but their long term use is limited block of the lingual, buccal, and inferior alveolar nerves by serious gastrointestinal side effects (6). A meta-anal- using two 1.8-mL capsules of 2% lidocaine-containing ysis clearly showed that high-doses of diclofenac (75 mg 1:100,000 epinephrine. Once anesthesia was adminis- twice daily) entails similar vascular risks to the aver- tered, surgery was started. A mucoperiosteal flap was age coxib regimen studied. Absolute excess risks were prepared by making a distal incision to the mandibular small but serious: compared with placebo, allocation to second molar along the anterior edge of the ascending a coxib or to diclofenac caused around three additional ramus of the mandible. This flap was utilized to close major vascular events per 1,000 participants annually, the surgical wound. Suturing was done with 4-0 silk, with one such event causing death (6,7). Meloxicam is and the number of sutures was documented. Difficulty a NSAID of the Oxicam class with selectivity toward of extraction was based on a modified Parant scale as COX-2 compared with COX-1. It is widely used in the follows: Grade I, extraction with forceps and elevators; treatment of osteoarthritis, rheumatoid arthritis, anky- Grade II, extraction by osteotomy; Grade III, extrac- losing spondylitis, and other rheumatological conditions tion by osteotomy and coronal section; and Grade IV, (8). In oral surgery, there are few studies concerning the extraction by osteotomy, root, and coronal section (13). use of meloxicam (8-14). In all cases, the duration of the surgical procedure (from The aim of this pilot study was to compare the analge- incision to final suture) was recorded. In each patient, a sic, anti-inflammatory and anti-trismus effect of a sin- partial impacted mandibular third molar was extracted. gle dose of diclofenac and meloxicam after mandibular - Assessment third molar extraction. The patients were administered 500 mg acetaminophen tablets and were instructed to take one or two pills for Material and Methods postsurgical medication at least 6 hours apart, accord- - Design ing to their requirements. Time of first rescue analgesic This study was designed as a double-blind, randomized, medication, i.e., time from the end of surgery until first parallel-group clinical trial, and was conducted in ac- intake of acetaminophen necessary for the patient, was cordance with the Declaration of Helsinki. The Ethics registered. At the end of the evaluation period (24 hours), Committee approved the study design. All of the sub- the patients returned the unused tablets. The pills were jects were informed of possible risks of oral surgery and counted to determine the number of pills consumed. Pa- experimental treatments, and they signed an institution- tients having no pain relief 30 min after taking 2 aceta- ally approved consent form. minophen tablets orally were given a 30 mg tablet of - Selection criteria sublingual ketorolac as rescue analgesic procedure due Inclusion criteria were age 18-30 years, either sex, free to therapeutic failure. Total analgesic consumption (oral of systemic disease, clinical and radiographic diagnosis acetaminophen and sublingual ketorolac) was evalu- of a mandibular impacted third molar with no pain asso- ated. e128 Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 (1):e127-34. Diclofenac versus meloxicam in oral surgery Fig. 1. Algorithm showing the progress of subjects through the trial phases. All patients completed the study. A 10 cm Visual Analog Scale (VAS) was employed exact test was employed. A p value <0.05 was consid- to assess pain. The VAS consisted of an interval scale ered a significant statistical difference. ranging from 0, representing no pain or discomfort, to 10, representing maximal pain or discomfort. The VAS Results report was recorded each hour for 12 hours after com- A total of 36 patients were enrolled in the study, and all pletion of surgery, and the last evaluation was conduct- patients were included in the statistical analysis.
Load more

Recommended publications
  • Meloxicam 15 Mg Orodispersible Tablets Meloxicam 15.0 Mg
    PACKAGE LEAFLET: INFORMATION FOR THE USER Meloxicam 15 mg Orodispersible Tablets Meloxicam 15.0 mg Read all of this leaflet carefully before you start taking may occur if you have serious blood loss or burns, surgery or low this medicine. fluid intake; Keep this leaflet. You may need to read it again. if you have ever been diagnosed with high potassium levels in If you have any further questions, please ask your doctor or the blood; pharmacist. Tell your doctor if you think any of these apply to you. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are Warning the same as yours. Medicines such as these Meloxicam tablets may be If any of the side effects become serious, or if you notice associated with a small increased risk of heart attack or any side effects not listed in this leaflet, please tell your doctor or stroke. Any risk is more likely with high doses and prolonged pharmacist. treatment. Do not exceed the recommended dose or duration of treatment. IN THIS LEAFLET: Discuss your treatment with your doctor or pharmacist if you have heart problems, have previously had a stroke or you think you 1. What Meloxicam orodispersible tablets are and what might be at risk of conditions such as high blood pressure, they are used for diabetes or high cholesterol, or if you are a smoker. 2 . Before you take Meloxicam tablets 3. How to take Meloxicam tablets Taking other medicines When you are taking Meloxicam tablets, do not take any other 4.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • (Ketorolac Tromethamine Tablets) Rx Only WARNING TORADOL
    TORADOL ORAL (ketorolac tromethamine tablets) Rx only WARNING TORADOLORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOLORAL and ketorolac tromethamine should not exceed 5 days. TORADOLORAL is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of TORADOLORAL beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES). TORADOL is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
    [Show full text]
  • Post Marketing Safety Data Analysis Reveals Increased Propensity For
    Post Marketing Safety Data Analysis Reveals Increased Propensity for Severe Cardiovascular and Cerebrovascular Side Effects in Patients Taking Celecoxib Compared to Other NSAIDs Aarti Patel, PharmD Candidate, Tigran Makunts, PharmD, Ruben Abagyan, Ph.D. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA ABSTRACT RESULTS Non-steroidal anti-inflammatory medications, NSAIDS, are commonly used Cardiovascular ADR Report Frequencies Cardiovascular ADR Report Frequencies Odds ratios of cardiovascular ADR worldwide for their analgesic and anti-inflammatory properties, and are deemed out of 100,202 NSAID Reports Among Male and Female Celecoxib Users among Celecoxib male users when safe for over the counter access. NSAIDS as a class have been associated with Myocardial Infarction 4.79 compared to female users cardiovascular, CV, cerebrovascular, CVA, and hypertension, side effects, with Cerebrovascular Accident 3.66 Cerebrovascular 9.69 Accident 11.23 rofecoxib being removed from the market due to these toxicities. However, the Chest Pain 0.85 Cerebrovascular Accident 1.18 risks of heart attack and stroke were deemed similar in all currently marketed Hypertension 0.73 Palpitations 0.49 1.77 NSAIDs. The growing concern over the potentially fatal CV and CVA warranted ADR Hypertension Hypertension 1.16 Hypotension 0.46 ADR 2.05 FEMALES further studies to quantify the associations these side effects. Here, we ADR Atrial Fibrillation MALES analyzed over twelve million reports in the FDA Adverse Event Reporting 0.29 Congestive Heart Failure 0.28 12.16 System, FAERS, to evaluate the reporting odds ratios of hypertension, Myocardial Infarction Myocardial Infarction 2.42 Tachycardia 0.25 myocardial infarction, and stroke in patients taking individual NSAIDs and 25.11 0 1 2 3 4 5 acetaminophen as monotherapy.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs Alter Nuclear Factor- Κβ in a Class Specific Manner
    Myers MJ et al. Treatment Dev Vet Pract 2020(1): 11-18. 10.33513/TDVP/2001-02 Treatments and Developments: Veterinary Practice OCIMUM Research Article Non-Steroidal Anti-Inflammatory Drugs Alter Nuclear Factor- κβ in A Class Specific Manner Abstract The capacity of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) to affect the NF-κβ dependent pathway was examined. The NSAIDs were co-cultured with RAW 264.7 cells transfected with a plasmid encoding Secreted Embryonic Alkaline Phosphatase (SEAP) under the control of NF-κβ. SEAP production was initiated by stimulating the cells with E. coli derived Lipopolysaccharide Michael J Myers*, Anne J Lewandowski and (LPS). Diclofenac, indomethacin, celecoxib, tolfenamic acid, flufenamic acid, Christine M Deaver and piroxicam inhibited SEAP production. Ketoprofen, phenylbutazone, Center for Veterinary Medicine, Office of Research aspirin, and acetaminophen did not affect SEAP production. TNFα stimulation Division of Applied Veterinary Research, USA of HEK293 cells transfected with a SEAP reporter gene under the control of NF-κβ was used to determine whether the NSAIDs were working directly on Received: 16 June 2020 the NF-κβ pathway or on TLR4 signaling. TNFα stimulated HEK293 cells Accepted: 20 July 2020 showed that diclofenac and flunixin inhibited SEAP production, but aspirin Version of Record Online: 31 July 2020 did not. Meloxicam and diclofenac both inhibited the amount of p65 released after LPS stimulation of the RAW 264.7 cells while flunixin did not affect Citation p65 release. Flunixin had no effect on an NF-κβ gel shift assay. These results demonstrate that NSAIDs in four of the six NSAID families can inhibit NF- Myers MJ, Lewandowski AJ, Deaver CM (2020) κβ pathway, albeit via different points in the pathway.
    [Show full text]
  • The Importance of COX-2 Inhibition for Aspirin Induced Asthma
    S54 Thorax 2000;55 (Suppl 2):S54–S56 Thorax: first published as 10.1136/thorax.55.suppl_2.S54 on 1 October 2000. Downloaded from The importance of COX-2 inhibition for aspirin induced asthma Alan Bennett There have been recent reviews of aspirin “specific” is used here to denote that the activ- induced asthma (AIA),12 the use of the ity is (usually) much greater against COX-2 COX-2 preferential inhibitor nimesulide in than against COX-1. Two drugs with a asthmatic patients intolerant to non-steroidal “preferential” status are nimesulide and mel- anti-inflammatory drugs (NSAIDs),3 and of oxicam, whereas two drugs that probably nimesulide in general.45 This paper discusses deserve the title “specific” are rofecoxib and the importance of inhibiting prostaglandin E2 celecoxib. (PGE2) synthesis in AIA, and the relative Nimesulide (4-nitro-2-phenoxymethane- safety of NSAIDs that preferentially inhibit sulphonanilide) is particularly important in COX-2. AIA because several studies have shown that it Aspirin and other NSAIDs cause broncho- is tolerated by most patients with the disorder constriction in about 10% of asthmatic to about the same extent as paracetamol. This subjects but NSAIDs relieve asthma in about sulphonanilide NSAID, which is eVective in 0.3%.2 This variability helps to show the com- treating a wide spectrum of inflammatory and plexity of the problem. Prostaglandins in painful conditions,7 was first marketed in 1985 human lung are formed by various tissues and and 10 years later it was found to be a cells, including bronchial muscle, epithelium, preferential inhibitor of COX-2.89Because it is and inflammatory cells,12 so the inhibition of not marketed in the USA, Japan, or the UK, prostaglandin formation can have numerous nimesulide is not well known in some parts of eVects.
    [Show full text]
  • 2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report Date: September 2003 Update 2 Report Date: May 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Mark Helfand, MD, MPH Kim Peterson, MS Tracy Dana, MLS Carol Roberts, BS Produced by Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically(see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 3 Drug Effectiveness Review Project TABLE OF CONTENTS Evidence Table 1. Systematic reviews…………………………………………………………………3 Evidence Table 2. Randomized-controlled trials………………………………………………………9 Evidence Table 3.
    [Show full text]
  • Mobic Tablets Meloxicam Consumer Medicine Information
    Mobic Tablets meloxicam Consumer Medicine Information What is in this leaflet Although Mobic can relieve the bypass graft or major vascular symptoms of pain and inflammation, surgery This leaflet answers some common it will not cure your condition. Mobic • have a disease of the heart with questions about Mobic. belongs to a family of medicines shortness of breath, and swelling called Non-Steroidal Anti- of the feet or lips due to fluid It does not contain all the available Inflammatory Drugs (NSAIDs). information. build-up These medicines work by relieving • experience bleeding from the It does not take the place of talking to pain and inflammation. your doctor or pharmacist. stomach, gut or any other Ask your doctor if you have any bleeding All medicines have risks and questions about why this medicine • benefits. Your doctor has weighed has been prescribed for you. had a stroke resulting from a the risks of you taking Mobic against bleed in the brain or have a Your doctor may have prescribed it bleeding disorder the benefits they expect it will have for another reason. for you. • had a heart attack This medicine is available only with • If you have any concerns about a doctor's prescription. have galactose intolerance taking this medicine, ask your • are pregnant or intend to become doctor or pharmacist. pregnant This leaflet was last updated on the • have a peptic (stomach) ulcer date at the end of this leaflet. More Before you take Mobic • have or have had inflammation of recent information may be available. the lining of the stomach or The latest Consumer Medicine When you must not take it Information is available from your bowel (e.g.
    [Show full text]
  • Drug Allergies & Cross-Sensitivities
    DRUG ALLERGIES & CROSS-SENSITIVITIES A Presentation for HealthTrust Members June 2, 2020 Vasyl Zbyrak, PharmD, PGY-1Pharmacy Resident Saint Barnabas Medical Center Kristine A. Sobolewski, PharmD, BCPS, Preceptor 2 Speaker & Preceptor Disclosures The presenter and his preceptor have no real or perceived conflicts of interest related to this presentation. Note: This program may contain the mention of suppliers, brands, products, services or drugs presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes and should not be perceived as an endorsement of any particular supplier, brand, product, service or drug. 3 Learning Objectives Pharmacists & Nurses: Distinguish the different drug class allergies and their mechanism of action Describe the most common drug allergies and characteristics of an allergic reaction Recommend alternative treatment options based on the drug allergy profile while evaluating the potential risk for the patient 4 Learning Objectives Pharmacy Technicians Identify the characteristics of an allergic reaction and common drug allergies Recognize the names of potentially inappropriate medications based on allergies and cross-sensitivities 5 Patient Case JG is 62 YO female presenting to the ED with pain 9/10. Patient was ordered morphine 4 mg IV push. Pain was relieved, but a rash appeared on her face with some flushing. Patient is not complaining of any other symptoms or shortness of breath. 6 Is the patient experiencing a drug allergy? 7 Adverse Drug Reactions A general term utilized to encompass any unwanted reaction to a medication and are broadly divided into Type A and B reactions Type A Type B • Reactions occurring in most • Drug hypersensitivity that is patients that are common relatively uncommon, rare and predictable and mostly unpredictable • Involves potential overdose, • Involves intolerances, side effects and drug idiosyncrasy, pseudoallergy interactions and drug allergies Source: Celik G, et al.
    [Show full text]
  • Motrin® Ibuprofen Tablets, USP
    Effective Date: 01/20/2007 Motrin® Ibuprofen Tablets, USP Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS). • MOTRIN tablets are contraindicated for treatment of peri- operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). DESCRIPTION MOTRIN tablets contain the active ingredient ibuprofen, which is (±) - 2 - (p - isobutylphenyl) propionic acid. Ibuprofen is a white powder with a melting point of 74-77° C and is very slightly soluble in water (<1 mg/mL) and readily soluble in organic solvents such as ethanol and acetone. The structural formula is represented below: MOTRIN tablets, a nonsteroidal anti-inflammatory drug (NSAID), is available in 400 mg, 600 mg, and 800 mg tablets for oral administration. Inactive ingredients: carnauba wax, colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, propylene glycol, titanium
    [Show full text]
  • Utah Medicaid Pharmacy and Therapeutics Committee Drug
    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Non-Selective Oral Nonsteroidal Anti-Inflammatory Drugs AHFS Classification: 28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents Diclofenac Etodolac Fenoprofen Flurbiprofen Ibuprofen Indomethacin Ketoprofen Ketorolac Mefenamic Acid Meloxicam Nabumetone Naproxen Oxaprozin Piroxicam Sulindac Tolmetin Final Report April 2018 Review prepared by: Elena Martinez Alonso, B.Pharm., Medical Writer Vicki Frydrych, B.Pharm., Pharm.D., Clinical Pharmacist Valerie Gonzales, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Research Assistant Professor, Clinical Pharmacist Michelle Fiander, MA, MLIS, Research Assistant Professor, Evidence Synthesis Librarian Joanne LaFleur, PharmD, MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved 1 Contents Executive Summary ...................................................................................................................................... 3 Introduction ................................................................................................................................................... 6 Table 1. FDA-Approved Oral Non-selective NSAIDs......................................................................... 7 Table 2. FDA-Approved Indication for Oral Non-selective NSAIDs ...............................................
    [Show full text]
  • How Does Meloxicam (Mobicox?) Compare to Other Nsaids and Csis
    The Rx Files: Q&A Summary February 2001 â Update on Meloxicam (Mobicoxâ) & COX-2 Selectivity COX-2 Selectivity/Specificity adverse GI events.10 This data must be cautiously interpreted wThere is a lot of discussion regarding the relative COX-2 due to the inherent limitations of the meta-analysis, such as selectivity of meloxicam compared to celecoxib (Celebrexâ) variability of trial outcomes, and the low dosage of meloxicam and rofecoxib (Vioxxâ). A December 2000 RxFiles Q&A used in most trials. Summary regarding meloxicam stated that it had “relatively wMeloxicam appears to have better GI tolerance than non- selective but not specific COX-2 inhibition” as discussed in selective NSAIDs. To what extent ulcers and complicated a variety of literature.1,2,3,4,5 Boehringer Ingelheim (Canada) ulcers are also reduced remains to be established. Ltd. (BICL) has been detailing meloxicam as an agent with wMajor trials evaluating the safety of the other COX-2 selective COX-2 selectivity comparable to celecoxib based on data drugs, celecoxib (Celebrexâ) and rofecoxib (Vioxxâ) have been from BICL sponsored work of Warner et al.6 This research published. These trials differ from the large-scale meloxicam measured NSAID inhibition of COX-1 when COX-2 trials as dosages were 2-4X higher than usually enzyme activity is inhibited by 80%. It found that both recommended and trial length was longer (see Table). meloxicam and celecoxib were 5-50 fold selective for COX- §The CLASS11 study compared celecoxib to non-selective 2, with rofecoxib being >50 fold COX-2 selective. The NSAIDs (ibuprofen and diclofenac).
    [Show full text]